UPDATE: MiMedx Group (MDXG) Reports Q3 EPS of $0.08, Offers Q4 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
MiMedx Announces Record Results For Third Quarter Of 2017 And Raises Full Year Revenue Guidance
October 26, 2017 2:00 PM EDTMARIETTA, Ga., Oct. 26, 2017 /PRNewswire/ --Â MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today its record results for the third quarter of 2017.
Third Quarter 2017 Financial HighlightsÂ
Q3 2017 revenue of $84.6 million exceeded MiMedx guidance range of $79 to $80 million Q3 2017 revenue grew 31% over Q3 2016 revenue Wound Care revenue of $61.9 million grew 24% over Q3 2016 Surgical, Sports... More